Dean&Francis
ISSN 2959-409X

Current Progress and Development of Cancer Vaccines

Jiaxin Zhou

Department of Biological Sciences, University of California, San Diego, USA

jiz154@ucsd.edu

Abstract:

mwymwAbstract:
Due to the accumulation of DNA damage over time, an increased human lifespan leads to higher cancer incidence and mortality rates, leading to the need for more effective prevention and treatment strategies. Cancer vaccines are emerging as an innovative and promising type of immunotherapy, offering the potential for personalized, less toxic treatments that enhance long-term immune surveillance and response. This review delves into the cutting-edge progress of cancer vaccine development, emphasizing their unique ability to empower the immune system to detect and destroy cancer. Despite significant progress, the development of these vaccines faces daunting challenges related to tumor diversity, immune suppression and evasion, and the complexity of vaccine production. The use of new technologies, including artificial intelligence and genomics, may be the key to overcoming these barriers. This paper explores how innovation is pushing the boundaries of what's possible in the fight against this unforgiving disease. The future of cancer therapy may just lie in a shot of hope.

Keywords: Cancer vaccine; immunotherapy; oncology; tumor microenvironment.

1. Introduction

Cancer treatments have made significant progress since the 1890s, with innovative cancer treatments like targeted therapy, immunotherapy, and gene therapy increasing cancer survival rates. Nevertheless, cancer remains a major global health issue and a dominant cause of death worldwide. The International Agency for Research on Cancer reported an estimated 19.3 million new cancer cases and 10 million cancer deaths globally in 2020. Furthermore, the global cancer burden in 2040 was projected to reach 28.4 million cases [1]. In the United States alone, about 2 million new cancer cases and more than 6 hundred thousand cancer-related deaths had been anticipated to occur in 2024, making cancer the second leading cause of death [2]. Aside from traditional treatments, including surgery, chemotherapy, and radiation therapy, which have made considerable progress in improving patient outcomes, more effective and innovative cancer treatments are needed because traditional treatments often come with significant side effects and, in many cases, fail to achieve long-

ISSN 2959-409X

term remission, especially in advanced or metastatic cancers.

In recent years, immunotherapy has emerged as a revolutionary approach to cancer treatment, aimed at stimulating, strengthening, or suppressing the immune system to help it recognize and eliminate cancer cells more effectively. Immunotherapy is considered the fourth pillar of cancer treatment, complementing the traditional approaches, due to its unique ability to provide targeted and personalized treatment for fewer side effects, induce long-lasting immune response to prevent cancer recurrence, and offer new treatment options for cancers that are resistant or poorly responsive to conventional therapies [3]. Among the various forms of immunotherapy, cancer vaccines are a key area of interest for research due to their various advantages and capabilities. This review summarizes the current progress in cancer vaccine development, including the differences between different types of cancer vaccines, their advantages and limitations, recent technological and clinical developments, and potential areas for improvement.

2. Progress and Development of Cancer Vaccines

The body's immune system was first used to combat cancer in the 1890s when Dr. William B. Coley, an American surgeon and the father of immunotherapy, observed that some cancer patients who had severe bacterial infections experienced remission or shrinkage of their tumors. He was then inspired to experiment by injecting cancer patients with mixtures of live and inactivated bacteria to stimulate the immune system. The mixture is composed of *Streptococcus pyogenes* and *Serratia marcescens* and is now known as Coley's toxins. Dr. Coley's work demonstrated that the immune system could be activated and utilized to fight cancer [4]. Even though the mechanisms of the therapy were not fully understood at the time, it laid the groundwork for modern cancer immunotherapy, eventually leading to the development of more sophisticated and targeted cancer vaccines.

Normal vaccines contain antigens made from weakened or harmless versions of the disease and train the body to recognize the agent as a threat. The immune system creates antibodies that destroy and memorize the pathogen so that it can more easily distinguish and eliminate that pathogen if exposed in the future [5]. Cancer vaccines, on the other hand, not only could prevent cancer by targeting infectious agents linked to cancer development but could also treat existing cancers by stimulating immune responses against tumor antigens.

Preventive vaccines are given to healthy individuals to reduce the risk of certain cancers from developing. Like traditional vaccines, these prophylactic vaccines protect the body from specific viruses known to cause cancer and are used before the person is exposed to or infected by the virus. Additionally, preventative vaccines can also be used to target individuals with chronic inflammatory conditions or early-stage lesions that may lead to cancer, as well as for those who have survived an initial tumor but remain at risk of developing another malignancy [6]. There are currently two preventive cancer vaccines approved by the United States Food and Drug Administration (FDA): the human papillomavirus (HPV) vaccine and the hepatitis B vaccine [5].

In contrast to preventive vaccines, therapeutic cancer vaccines are designed for individuals already diagnosed with cancer to help the immune system fight the disease. These vaccines typically contain two main components: antigens and adjuvants [7]. Antigens are distinctive markers on the surface of cells that often help differentiate cancer cells from normal cells, while adjuvants are substances that alert the immune system of the presence of cancer and strengthen the immune response. Together, the combination induces an immune response against cancer, helps the body remember cancer cells to prevent recurrence, and either eliminates residual cancer cells after other treatments or inhibits tumor growth and spread. Some cancer vaccines are personalized and created from a patient's own tumor sample, while others target specific antigens found on certain types of tumors. These antigens include tumor-specific antigens (TSAs), exclusively expressed on cancer cells but not on healthy cells, and tumor-associated antigens (TAAs), which are overexpressed on tumor cells but may be present at lower levels in other healthy cells [8]. This overview of cancer vaccine mechanisms and targets provides a foundation for exploring the diverse approaches currently under research and development. Each of these approaches, including cell-based vaccines, induced pluripotent stem cell-based vaccines, in situ vaccines, microbial vector vaccines, peptide vaccines, nucleic acid-based vaccines, and exosome vaccines, represents a unique strategy to fight cancer.

2.1 Cell-Based Vaccines

Cell-based vaccines use either cancer cells or immune cells, such as dendritic cells (DCs), to stimulate an immune response against cancer cells. These cells are collected, activated or edited in a laboratory, and reintroduced into the patient's body. Allogeneic vaccines use cells from donors or cell lines and can be produced rather quickly but lack personalization. Autologous vaccines, on

the other hand, use patients' own cells to ensure antigen compatibility yet require more time and resources. [9]. These vaccines mimic the natural immune process, often presenting a wide range of tumor antigens that stimulate an adaptive immune response. This broad range of tumor antigens allows these vaccines to target multiple cancer pathways without needing to identify specific antigens in advance [10]. However, the complex and costly production processes for autologous vaccines can limit their effectiveness [9].

Dendritic cell vaccines use DCs, which are antigen-presenting cells (APCs) [8]. DCs are collected from a patient's blood and then modified with specific tumor antigens, either from tumor cells or specific proteins associated with cancer, in the laboratory [9]. Once the DCs are reintroduced into the patient's body, they present the tumor antigens to T cells, triggering an adaptive immune response [11]. The most well-known DC vaccine is Sipuleucel-T (Provenge), the first therapeutic cancer vaccine approved by the FDA [12]. It is customized for each patient and uses their own immune cells. Blood is collected from the patient to obtain peripheral blood mononuclear cells (PBMCs), including DCs. These PBMCs are exposed to a prostate cancer-associate antigen linked to an immune cell activator and then reinfused into the patient to provoke an immune response. Clinical results demonstrated that Sipuleucel-T extended survival in men with metastatic prostate cancer, and its approval paved the way for the development of other DC-based and cellular immunotherapies [11]. Requiring a sophisticated laboratory process to culture and manipulate cells tailored for individual patients, DC vaccines are comparatively expensive and labor-intensive to produce, but their specificity allows for selective targeting of certain cancer cells.

Another type of cell-based vaccine is the whole-cell vaccine, which exposes the immune system to the entire tumor cell or tumor cell lysates, providing a broader range of antigens that are naturally found on tumor cells [9]. These vaccines use either autologous or allogeneic tumor cells. Often genetically modified to express immune-stimulating cytokines like granulocyte-macrophage colony-stimulating factor (GM-CSF), whole-cell vaccines can enhance DC recruitment, antigen absorption, and antigen exposure to T cells, triggering a strong immune response. Due to the broad antigen presentation, these vaccines bypass the need to identify specific antigens and can target multiple tumor antigens simultaneously, potentially eliciting a broader immune response. There aren't any FDA-approved whole-cell vaccines yet, but some, such as GVAX and Oncovax, are in clinical trials. These vaccines have shown promise in early trials for cancers such as prostate, colon, and melanoma, but their clinical results have been mixed, with ongoing efforts to improve their efficacy through combination therapies with immune checkpoint inhibitors [8].

2.2 Induced Pluripotent Stem Cell-Based Vaccines

Induced pluripotent stem cell (iPSC)-based vaccines use either autologous or allogeneic reprogrammed somatic cells that share gene expressions with both embryonic stem cells and cancer cells [8]. Unlike vaccines that target specific tumor antigens, iPSC-based vaccines can present a broader range of TAAs, including those associated with cancer stem cells (CSCs), which are resistant to conventional therapies [13]. Due to the broad range of antigens, the vaccine can stimulate a strong immune response, activate CD4+ and CD8+ T cells, and modify the tumor microenvironment (TME) [8]. In addition, iPSC vaccines can also be combined with agents like histone deacetylase inhibitors (HDACi) to enhance their efficacy by reducing immunosuppressive cells that are often present in the TME such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) [13]. Unfortunately, there are currently no FDA-approved iPSC-based cancer vaccines due to challenges in production and safety concerns such as the risk of teratoma formation despite promising results in preventing tumor growth and reducing metastasis shown in preclinical studies [9].

2.3 In Situ Cancer Vaccines

In situ vaccines are different from other cancer vaccines as they generate an immune response directly within the TME instead of requiring an external injection of modified cells. These vaccines are not personalized, and by using general antigens in the TME, they are created and activated directly in the patient's body. Developed in the early 2000s, with TriMix being a pioneering example, these vaccines activate and mobilize DCs within the TME to present TSAs to the immune system, leading to a targeted immune attack on cancer cells. In situ vaccines modify the TME by promoting the infiltration of effector T cells and inducing immunogenic cell death, which helps eliminate tumors and prevent metastasis. Unlike traditional vaccines, which are administered systemically, in situ vaccines limit side effects by focusing the immune response locally. While promising in preclinical and clinical studies, no FDA-approved in situ cancer vaccines are available yet due to inadequate tumor antigen release, antigen processing issues, and the suppressive TME [9].

2.4 Microbial Vector Vaccines

Microbial vector vaccines utilize modified microbes such

ISSN 2959-409X

as viruses or bacteria to deliver tumor antigens. These vaccines take advantage of microbes' natural ability to infect host cells, ensuring both innate and adaptive immune systems are engaged effectively [14]. By using live vectors as vehicles to deliver tumor antigens directly to antigen-presenting cells, microbial vector vaccines enhance the presentation of these antigens to immune cells, leading to a more effective and prolonged immune response. These vectors are engineered to be safe while maintaining their immunogenicity, offering an advantage over traditional vaccines and making them potent tools for triggering immune cells like T cells to recognize and destroy cancer cells. However, despite their effectiveness in inducing strong immune responses, live viral and bacterial vectors face challenges in clinical applications because the host's immune system tends to neutralize the vectors after the initial dose, leading to the need for multiple booster doses [7].

One type of microbial vector vaccine is the viral-based vaccines, which use modified viruses as carriers to introduce cancer antigens into the body. When the virus replicates, it presents tumor antigens to the immune system, which activates natural killer (NK) cells and T cells to eliminate cancer cells that express those antigens. The viruses that are used for these vaccines are usually attenuated or non-replicating so that they can infect cancer cells or immune cells without causing disease. Oncolytic viruses can be used to improve the effectiveness of these vaccines due to their ability to specifically target, infect, and kill cancer cells while avoiding healthy cells. The TME is often immunosuppressive, which can hinder the effectiveness of cancer vaccines, but oncolytic viruses are able to make the TME more favorable for immune activation. These viruses selectively replicate in tumor cells until the cancer cell lyses to release new viral particles, tumor antigens, and other immunogenic factors like PAMPs, DAMPs, and neoepitopes to further stimulate immune responses. The newly released viruses can infect neighboring cancer cells as well. Clinical trials of oncolytic viruses have shown great results with minimal toxicity. Talimogene laherparepvec (T-VEC) is an FDA-approved vaccine that uses herpes simplex virus (HSV) to treat metastatic melanoma [9]. Adenoviruses (Ads) can also be genetically engineered into oncolytic viruses [15]. Another virus that could be used is the arenavirus, specifically lymphocytic choriomeningitis virus (LCMV). Unlike many oncolytic viruses, LCMV is noncytopathic, meaning it doesn't kill cancer cells directly. Instead, it blocks interferon (IFN) pathways and uses antigen masking to escape early immune detection, allowing it to persist within tumors, which leads to immune activation and the recruitment of NK cells and cytotoxic CD8+ T cells [16]. Unlike other cancer vaccines that may struggle to penetrate the TME, viral-based vaccines have the advantage of the virus's natural mechanisms to bypass immune suppression and create a more inflammatory, anti-tumor environment. However, pre-existing immunity to viral vectors may reduce vaccine effectiveness, and potential adverse effects like inflammation are also a concern for viral-based vaccines. To overcome these difficulties and improve vaccine efficacy, combining them with other immunotherapies, targeting multiple antigens, and optimizing treatment protocols are all strategies that are being explored by researchers [9].

Bacteria-based vaccines, another type of microbial vector vaccines, use live attenuated bacteria, bacterial components, or bacterial derivatives to deliver therapeutic agents like cytokines or chemotherapeutic agents directly into the TME. Directing bacterial-based vaccines to the TME allows for a more targeted immune response, reducing systemic toxicity, and increasing therapeutic efficacy. These vaccines have great potential in reducing tumor proliferation, preventing metastasis, and minimizing recurrence. Bacterial vectors tested in clinical trials, including Listeria monocytogenes, Lactobacillus casei, Lactobacillus lactis, and Salmonella can trigger both innate and adaptive immune responses and are modified to express cytokines and TAAs, stimulating T and NK cells to target cancer cells specifically [9]. Bacterial vaccines offer significant benefits, yet safety concerns due to bacterial toxicity and variability in immune responses remain challenges for clinical application, especially because some bacteria are associated with cancer risk, so careful selection and modification are required to ensure the efficacy of bacterial-based vaccines without adverse effects [17].

2.5 Peptide Vaccines

Peptide vaccines consist of short sequences of amino acids that mimic TAAs and TSAs to stimulate an immune response directly against a wide range of carcinomas. These vaccines are processed by APCs like DCs which present the peptides on major histocompatibility complex (MHC) molecules to CD4+ and CD8+ T cells, and activate cytotoxic T lymphocytes (CTLs) that target and kill cancer cells expressing the TAAs. One of the main advantages of peptide vaccines is their ability to be synthesized and modified easily, making them a versatile option in vaccine development [9]. Peptide vaccines targeting specific mutations, such as KRAS G12D, have demonstrated the potential for eliciting specific immune responses in clinical trials, though their effectiveness in tumor reduction has been limited [18]. Research continues to explore ways to enhance their efficacy, including the use of adjuvants like GM-CSF and combination therapies with immune check-

point inhibitors and other immune modulators to target multiple tumor evasion mechanisms [19].

2.6 Nucleic acid-based Vaccines

Nucleic acid-based vaccines use genetic material, either DNA or RNA, to instruct host cells to produce antigens associated with specific pathogens or cancer cells. Unlike traditional vaccines that often introduce a weakened or inactivated pathogen, nucleic acid vaccines deliver genetic instructions required to produce the antigen directly into the body, utilizing the body's cellular mechanisms to synthesize the protein. One advantage of these vaccines is that they can carry the complete genetic sequence of tumor antigens, allowing the immune system to recognize and react to multiple parts of the antigen, leading to a comprehensive T-cell response. Their capability of delivering multiple antigens and targeting a range of TAAs or specific mutations in tumor cells enhances both antibody-mediated and cell-mediated immune responses, which increases the likelihood of the vaccine overcoming resistance mechanisms. Moreover, these vaccines can activate DCs and increase levels of pro-inflammatory cytokines, enhancing the immune reaction. They can also include genes that fuse different parts of antigens or immune stimulatory molecules to boost the memory response of T-helper cells for long-lasting immunity [9].

DNA vaccines use plasmid DNA engineered to carry genes encoding specific tumor antigens to the body, where the plasmids are taken up by cells, particularly APCs like DCs, which then use the encoded instructions to produce the antigen and display it on their surface. This presentation activates CD8+ cytotoxic T cells to kill cancerous cells. The presence of unmethylated CpG motifs in the plasmid DNA further enhances immune activation by mimicking bacterial DNA. Advanced delivery methods such as electroporation, sonoporation, gene guns, and DNA tattooing enhance their effectiveness, although concerns about integration into the host genome remain. Furthermore, DNA vaccines often fail to completely evade immune system recognition without the help of combination therapy [9]. Regardless, trials using KRAS DNA vaccines in BALB/c mouse models with lung cancer showed that these vaccines could effectively enhance CTL and Th1 CD4+ T immune responses, reducing cancer nodules with KRAS G12D mutations [18].

RNA vaccines, especially those that use messenger RNA (mRNA), offer a promising alternative to traditional and DNA-based vaccines. These vaccines provide cells with mRNA sequences that directly translate into disease-specific antigens. The host cell performs the translation upon delivery, leading to antigen production that stimulates an immune response. Not only can mRNA vaccines work in both dividing and non-dividing cells, but they also do not integrate into the host genome and are naturally degraded by the body after a short period, avoiding the risk of long-term side effects associated with DNA vaccines. Recent successes with mRNA vaccines against COVID-19 have proved their potential for rapid development and high efficacy, with the technology allowing for precise targeting of specific strains of viruses or mutations in cancer cells. Innovations in stabilizing RNA molecules and enhancing delivery mechanisms, such as lipid nanoparticles, have overcome previous challenges of RNA vaccine fragility and inefficacy [9]. RNA vaccines' flexibility to be quickly designed from genetic sequences makes them especially advantageous for developing personalized cancer treatments, where they can be engineered to target specific mutations specifically for an individual's tumor [20].

2.7 Exosome-based Vaccines

Tumor-derived exosomes contain many cancer-specific markers such as tumor antigens, MHC molecules, heat-shock proteins, and inducible co-stimulatory molecules that can be found in the TME. Exosomes have shown promise in vaccine development due to their nature of carrying signaling molecules that can regulate the TME. They can also deliver functional RNAs to target cells, combining with immunostimulatory agents to induce strong CD8+ T cell anti-tumor responses. Studies show that exosomes can deliver functional RNAs and chemotherapeutic drugs across biological barriers to treat brain cancer. Despite its capabilities, no exosome-based vaccines have been approved by the FDA yet. One significant challenge of using exosomes is that they can transport factors that promote epithelial-mesenchymal transition (EMT), which potentially leads to increased tumor invasiveness and resistance to therapy [9].

3. Limitations of Vaccine Development

Recent advances in molecular biology, immunology, and biotechnology have accelerated the development of cancer vaccines, leading to the approval and commercialization of several therapies. Meanwhile, other promising candidates are currently undergoing clinical trials. However, despite the advancements in cancer immunotherapy and its successful treatment of a variety of cancers, only a minority of patients achieve long-term survival. This reflects the intricate nature of the immune system and the complexity of cancer as a disease influenced by genetic alterations and immune evasion tactics. The discovery of effective cancer vaccines faces numerous challenges such as tumor heterogeneity, immunosuppressive environments,

ISSN 2959-409X

immune evasion, and patient immune response variability. Moreover, identifying suitable antigens without causing autoimmunity, as well as optimizing vaccine design and delivery methods are some other difficulties in cancer vaccine research [9]. The challenges can be summarized into the following categories: biological, technical, and logistical issues.

One of the primary biological issues that cancer vaccines face is the suppressive TME, which can disrupt the efficacy of activated immune cells in recognizing and attacking tumor cells. This suppression allows tumor cells to develop mechanisms to evade immune detection, inhibiting the vaccine's effectiveness. Specifically, it is important to understand the molecular and cellular drivers for primary immune escape, where tumors initially evade the immune system, versus secondary escape, where tumors evolve mechanisms to escape after an initial immune response. That evolution can lead to treatment resistance and cancer progression despite initial responses to therapy. Moreover, response to immunotherapy varies greatly among patients due to differences in the genetic makeup of tumors, the TME, and immune response mechanisms. This variability also makes vaccine development difficult and necessitates personalized treatment [21]. Moreover, immune tolerance to the encoded antigens, especially in treatments like nucleic acid-based vaccines can limit long-term efficacy, meaning additional doses or adjunct therapies would be needed [9]. Furthermore, limitations of existing preclinical models like murine models, which do not fully mimic the human immune environment, lead to countless clinical outcomes that fail to match the promising results seen in preclinical studies [22]. Differences include the composition of immune cells, tumor antigens, and the mechanisms of immune suppression that arise from prolonged exposure to antigens [21]. In general, the complexity of the human immune system which involves intricate interactions between immune cells and tumors emphasizes the need for a better understanding of tumor-immune interactions.

Technical challenges also play a significant role in the development of cancer vaccines. The isolation and cultivation of patient-specific immune cells for cell-based vaccines require extensive resources and specialized expertise, leading to high production costs. Similarly, iPSC-based vaccines need extensive preclinical safety assessments to avoid risks like tumor formation or undesired cellular responses. Additionally, the need for specialized delivery systems to ensure the effective transfection of nucleic acids is another technical issue [9]. The complexity of gene editing technology such as CRISPR-Cas9 is also a challenge due to the need to ensure the right genes are edited to achieve the desired immune response without causing unwanted side effects or genetic instability [22].

Logistically, the production and distribution of cancer vaccines face great obstacles that can limit their accessibility and practicality. The personalized nature of many cancer vaccines, particularly cell-based types, complicates mass production and distribution because each patient's cancer is unique, which requires vaccines that are specifically tailored to their tumor's antigens. This level of customization impacts the scalability and economic feasibility of those vaccines. Furthermore, ethical considerations for vaccines involving genetic manipulation or embryonic stem cells, are also a great concern [9].

4. Strategies to Improve Cancer Vaccines

As research advances, several strategies are emerging that could significantly increase the effectiveness of cancer vaccines. These strategies include combination therapy, artificial intelligence (AI), and other pioneering techniques and technologies that can be incorporated into vaccine development and personalization.

Combining cancer vaccines with other treatments, such as checkpoint inhibitors and modulators of the TME, could drastically improve therapeutic outcomes. Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by blocking the mechanisms that tumors use to evade the immune system. Combining ICIs with vaccines can both initiate and sustain a powerful immune response against cancer [23]. Moreover, combination therapies with ICIs could reinvigorate exhausted T cells that become ineffective over time [24]. It is critical to strategically combine different therapeutic agents to enhance the efficacy of cancer vaccines for the optimization of long-term survival. Considerations of dosing and timing, avoiding overlapping toxicities while maximizing synergistic effects, and using a multi-pronged approach to attack cancer from several angles simultaneously are all ways to enhance the effectiveness of the treatment. Additionally, combining endogenous immunity, the body's natural immune response, and synthetic immunity, artificially induced response, in a treatment regimen may be synergistic and provide more durable protection against cancer [21].

Using humanized mouse models that are genetically engineered to better mimic human tumor immunogenicity, organoids, mammospheres derived from human cancer stem cells, and ex vivo models that allow for real-time observation of tumor-immune interactions can improve the relevance of pre-clinical models to human conditions [21]. Indirect modulation of the TME by altering the gut microbiome, modifying the blood vessels within tumors, and using cytokines can overcome immunotherapy resistance

and enhance immunogenicity [25].

Artificial intelligence, emerging rapidly as a transformative tool in cancer immunotherapy, is being used to predict treatment responses, improve diagnostic accuracy, and optimize treatment strategies. AI algorithms can analyze vast amounts of data from scientific research, clinical trials, and specialized databases to identify potential antigens and predict how the immune system will respond to them. Specifically, AI can evaluate immune signatures, histological data, and medical imaging to determine immunotherapy outcomes. This approach not only speeds up the development process but also increases the likelihood of success in early-stage trials. AI can also assist in personalizing vaccines by analyzing vast amounts of genetic data to identify optimal gene targets for editing [26]. AI can improve the efficiency and precision of cancer vaccine production and make personalized medicine more accessible and effective. More generally, AI is also used to improve clinical diagnostic accuracy, standardize immunotherapy response assessment, personalization, and the overall effectiveness of cancer immunotherapy. Nevertheless, AI has its own limitations and is not to replace clinicians.

5. Conclusions

The development of cancer vaccines offers a potentially powerful tool to both prevent and treat various forms of cancer. Over the past few decades, advancements in molecular biology, immunology, and biotechnology have significantly helped cancer vaccines evolve. While these developments hold immense promise, there remain challenges that must be addressed for cancer vaccines to reach their full potential. Biological challenges such as tumor heterogeneity, immune evasion, and the immunosuppressive nature of the tumor microenvironment, as well as technical challenges of producing personalized vaccines and ensuring effective delivery mechanisms are all complicated problems waiting to be solved. However, ongoing research exploring innovative solutions such as combination therapies, personalized neoantigen vaccines, and the integration of new technologies such as artificial intelligence is expected to revolutionize vaccine design, allowing for more precise and effective treatments customized for individual patients. As our understanding of the immune system and cancer biology continues to evolve, cancer vaccines will surely offer new hope for patients with cancers that are resistant or poorly responsive to conventional treatments. With time, cancer vaccines have the potential to not only improve patient outcomes but also transform cancer into a more manageable disease, reducing its global burden and saving countless lives.

References

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–49.

[2] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024;74(1):12–49.

[3] Chiang CLL, Kandalaft LE. Chapter 2 - Tumor lysates cancer vaccine. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Aug 24]. p. 21–49. Available from: https://www.sciencedirect.com/science/article/pii/B9780128239018000017

[4] Abbott M, Ustoyev Y. Cancer and the Immune System: The History and Background of Immunotherapy. Seminars in Oncology Nursing. 2019 Oct 1;35(5):150923.

[5] Liu N, Xiao X, Zhang Z, Mao C, Wan M, Shen J. Advances in Cancer Vaccine Research. ACS Biomater Sci Eng. 2023 Nov 13;9(11):5999–6023.

[6] Jacqueline C, Finn OJ. Chapter 3 - Tumor antigens for preventative cancer vaccines. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Aug 24]. p. 51–74. Available from: https://www.sciencedirect.com/science/article/pii/B9780128239018000066

[7] Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley AG, McArdle SEB. Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. Frontiers in Immunology [Internet]. 2021 Feb 17 [cited 2024 Aug 24];11. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.615240/full

[8] Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. Journal of Leukocyte Biology. 2020 Oct 1;108(4):1455–89.

[9] Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A, et al. Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review. Cells. 2023;12(17):2159.

[10] Tiwari A, Alcover K, Carpenter E, Thomas K, Krum J, Nissen A, et al. Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis. Human Vaccines & Immunotherapeutics. 2024 Dec 31;20(1):2323256.

[11] Munson PV, Butterfield LH, Adamik J. Chapter 7 - Novel dendritic cell vaccine strategies. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Sep 8]. p. 109–35. Available from: https://www.sciencedirect.com/science/article/pii/B9780128239018000030

[12] Lee KW, Yam JWP, Mao X. Dendritic Cell Vaccines: A

ISSN 2959-409X

Shift from Conventional Approach to New Generations. Cells. 2023 Jan;12(17):2147.

[13] Kishi M, Asgarova A, Desterke C, Chaker D, Artus J, Turhan AG, et al. Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy. Front Med [Internet]. 2021 Dec 10 [cited 2024 Sep 9];8. Available from: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.729018/full

[14] Yan F, Cowell LG, Tomkies A, Day AT. Therapeutic Vaccination for HPV-Mediated Cancers. Curr Otorhinolaryngol Rep. 2023 Mar 1;11(1):44–61.

[15] Tseha ST. Role of Adenoviruses in Cancer Therapy. Front Oncol [Internet]. 2022 Jun 9 [cited 2024 Sep 14];12. Available from: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.772659/full

[16] Stachura P, Stencel O, Lu Z, Borkhardt A, Pandyra AA. Arenaviruses: Old viruses present new solutions for cancer therapy. Front Immunol [Internet]. 2023 Mar 24 [cited 2024 Sep 14];14. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1110522/full

[17] Zhou M, Tang Y, Xu W, Hao X, Li Y, Huang S, et al. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Front Immunol [Internet]. 2023 Aug 3 [cited 2024 Sep 14];14. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1140463/full

[18] Zhang Y, Ma JA, Zhang HX, Jiang YN, Luo WH. Cancer vaccines: Targeting KRAS-driven cancers. Expert Review of Vaccines. 2020 Feb 1;19(2):163–73.

[19] Hamilton DH, Schlom J, Jochems C. Chapter 9 - Peptide-based vaccines. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Aug 24]. p. 155–73. Available from: https://www.sciencedirect.com/science/article/pii/B978012823901800008X

[20] Conforti A, Palombo F, Aurisicchio L. Chapter 13 - Nucleic acid-based vaccines. In: Buonaguro L, Van Der Burg S, editors. Cancer Vaccines as Immunotherapy of Cancer [Internet]. Academic Press; 2022 [cited 2024 Aug 24]. p. 227–45. Available from: https://www.sciencedirect.com/science/article/pii/B9780128239018000029

[21] Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020 Jan 14;52(1):17-35.

[22] Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Sig Transduct Target Ther. 2023 Dec 13;8(1):1–23.

[23] Depil S, Bonaventura P, Alcazer V. Cancer vaccines: what's next? Oncotarget. 2019 Jun 18;10(40):3985–7.

[24] Redwood AJ, Dick IM, Creaney J, Robinson BWS. What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. OncoImmunology. 2022 Dec 31;11(1):2038403.

[25] Murciano-Goroff YR, Warner AB, Wolchok JD. The future of cancer immunotherapy: microenvironment-targeting combinations. Cell Res. 2020 Jun;30(6):507-19.

[26] Maserat E. Integration of Artificial Intelligence and CRISPR/Cas9 System for Vaccine Design. Cancer Inform. 2022 Jan 1;21:11769351221140102.